Development of Polar Organic Mode Chromatographic Method by Polysaccharide-Based Immobilized Chiral Selector and Validation for the Determination of the Enantiopurity of Novel Mineralocorticoid Receptor Antagonist Atropisomer–Esaxerenone

Esaxerenone is a new nonsteroidal mineralocorticoid receptor antagonist utilized to treat high blood pressure. Chemically, esaxerenone is a pyrrole derivative consisting of hindered rotation, which results in stereoisomers named atropisomers. Currently, no methods exist for the separation and quantification of these atropisomers. A new and accurate chiral liquid chromatographic technique was developed and validated to estimate the enantiomeric purity of esaxerenone. Polar organic chiral separation was carried out on an immobilized amylose-based chiral stationary phase (Chiralpak IG) with methanol:acetonitrile:diethylamine (9:1:0.1, v/v/v) mixture as a mobile phase. The total runtime was 15 min, and the resolution (R_s) between the atropisomers was more than 3.0. The detection and quantification thresholds for the R-atropisomer were found to be 0.03 and 0.1 µg mL^?1, respectively, for a test concentration of esaxerenone (1000 µg mL^?1). Over the range from the limit of quantification to 0.3 percent, the method's linearity for the R-atropisomer was excellent (R²?>?0.999). The R-atropisomer recovery varied from 95 to 102%, confirming the method’s good accuracy. For a 48-h research period, the chemical was shown to be stable.

     

Enantioseparation of DPP-4 Inhibitors on Immobilized Crown Ether-Based Chiral Stationary Phase

A group of DPP-4 inhibitors such as alogliptin, linagliptin and saxagliptin were selected for enantioseparation for this study. Crown ether columns contain a chiral crown ether ring as a chiral selector is suitable for the compounds having primary amino groups. Since the selected compounds contain free amino groups, a crown ether column was selected for enantiomeric separation of dipeptidyl peptidase-4 inhibitors. Dipeptidyl peptidase-4 inhibitors are a class of oral hypoglycemics that block dipeptidyl peptidase-4 enzyme and can be used to treat diabetes mellitus type 2. A sensitive HPLC method was developed to separate the enantiomers of each dipeptidyl peptidase-4 inhibitor. Effects of various parameters such as type of solvents, selection of additives, effect of pH and column temperature on chromatographic results were studied. The optimal conditions for the chiral separation of dipeptidyl peptidase-4 inhibitors without any derivatization were investigated.